
Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript
Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha6/18/2026Neutral
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.69M |
| Operating Margin | 0.00% |
| Return on Equity | -108.20% |
| Return on Assets | -26.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.90 |
| Price-to-Book | 0.84 |
| Price-to-Sales (TTM) | 160.10 |
| EV/Revenue | - |
| EV/EBITDA | 11.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $106.46M |
| Float | $89.12M |
| % Insiders | 8.44% |
| % Institutions | 14.66% |

Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript

CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the first quarter ended March 31, 2026.

CAMBRIDGE, Mass., April 15, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) today announced its latest purchase of 9,163.32 ZEC for $2,150,000 at an average purchase price of $234.63 per ZEC and launched its new website and investor dashboard at cypherpunk.com.